2022-RA-1058-ESGO Developing infrastructure for molecular profiling for all in ovarian cancer (DEMO). (20th October 2022)

• Record Type: Journal Article
• Authors: Leung, Elaine; Funingana, Gabriel; Bird, Lisa; Alcaraz, Marie-Lyne; Ang, Joo Ern; Parkinson, Christine; Jimenez-Linan, Merche; Freeman, Sue; Spencer, Catherine; Winning, Julie; Ganesan, Raji; Williams, Sarah; Ong, Kai Ren; Abedin, Parveen; Boyle, William; Sundar, Sudha; Balega, Janos; Brenton, James
• Is Part Of: International journal of gynecological cancer. Volume 32(2022)Supplement 2
• Page Start: A292
• Page End: A292
• Publication Date: 2022-10-20
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2022-ESGO.620
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Introduction/Background: The lack of patient engagement and biopsy quality could both reduce the number of successful molecular tests performed after the diagnosis of ovarian cancer. DEMO is a multi-centre quality improvement study that aims to improve the uptake and success rates of tumoural and germline molecular testing in ovarian cancer.The two lead sites have vastly different patient demographics. One in 7 (15%) women diagnosed in Birmingham are non-Caucasian with high number of patients requiring interpreters for their consultations, whilst patients diagnosed in Cambridge are mostly Caucasian and fluent in English. Methodology: The three components of DEMO include: 1) the establishment of a patient advisory group to co-produce a multimedia, multilingual patient information package to support informed decision making 2) the use of improvement methodology to analyse existing diagnostic pathways 3) the development of a multidisciplinary consensus guideline to improve the current biopsy pathways for molecular profiling. Results: Our initial retrospective audit (n=75; January-August 2021) demonstrated high tumoural (BRCA or Homologous Repair Deficiency) testing failure rates of 25% (3/12) and 35% (11/31) of samples from image-guided biopsies and post-chemotherapy resections, respectively. A prospective audit pathway has been agreed to inform future practice.In addition, the first patients advisory group discussion in June 2022 has provided a qualitative narrative on patients' perceptions on molecular testing and explore how patients would like such complex information conveyed to support patient information package development. Conclusion: Supporting informed decision making for all and establish auditable biopsy pathways are crucial for the implementation of molecular profiling to improve ovarian cancer care.